The US Patent and Trademark Office (USPTO) has granted an US patent to the InSite Vision’s DuraSite 2 next-generation enhanced drug delivery system, which will be valid up to 2029 for internal pipeline and partnering.
Offering a broad platform for developing topically delivered ocular drugs, the DuraSite 2 enhances tissue penetration to improve efficacy and dosing convenience.
InSite Vision CEO Timothy Ruane said, "DuraSite 2 has the potential to significantly increase efficacy and reduce dosing requirements for topically delivered ophthalmic drugs."
"Based on its ability to significantly improve drug retention and penetration into the tissues of the eye, we believe DuraSite 2 could serve as a standard drug delivery technology across ophthalmic therapeutics."
The company is also considering using the DuraSite 2 platform in the development of all future InSite Vision pipeline products and is also looking for partners through licensing agreements.
Compared to the same product alone or formulated with InSite Vision's DuraSite technology, a drug formulated with DuraSite 2 demonstrated significantly enhanced retention on the eye and tissue penetration.
The research result underlines that the DuraSite 2 formulation achieved more than 2x and 4x concentrations in the aqueous humor of the eye as compared to the DuraSite formulation or marketed drug, respectively.
Due to better tissue penetration, the DuraSite 2 can be used in the treatment of back-of-the-eye diseases with a topical eye drop when formulated with drugs that must currently be administered by injection.
